Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma a systematic review and meta-analysis

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 756-765

  Huo, Ya Ruth ^a   Eslick, Guy D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; HUMAN; LIVER NEOPLASMS; META ANALYSIS; MORTALITY; ODDS RATIO; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMORADIOTHERAPY; HUMANS; LIVER NEOPLASMS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84965092090     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2189     Document Type: Article

References (63)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2014. http://globocan.iarc.fr. Accessed February 24, 2015.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485-1491.
4. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236.
5. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40 (3):225-235.
6. Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii41-vii48.
7. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224 (1):47-54.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429-442.
9. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005;25(6): 1189-1196.
10. Kim KH, Kim MS, Chang JS, Han KH, Kim Y, Seong J. Therapeutic benefit of radiotherapy in huge (>10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34(5):784-794.
11. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006;106(8):1653-1663.
12. Fuss M, Salter BJ, Herman TS, Thomas CR Jr. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology. 2004;127(5)(suppl 1):S206-S217
13. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e447-e453.
14. Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2009;92(2):184-194.
15. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol. 2001;16(6):660-665.
16. Seong J, Park HC, Han KH, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res. 2003;27(1):30-35.
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64.
18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
22. Orwin R. A fail-safe N for effect size in meta-analysis. journal of educational statistics. J Educ Stat. 1983;8:157-159.
23. Wang G, Shen W, Song M, Xu H. Results of combined treatment with transcatheter hepatic arterial chemoembolization and whole-liver irradiation with the moving strip technique in unresectable hepatocellular carcinoma. J Clin Oncol. 2000;5:380-385. doi:10.1007/PL0001206.
24. Shang Y, You XX, Xu HY, Chen MC. Prospective randomized clinical study of transcatheter arterial chemoembolization, combined with three-dimensional conformal radiotherapy for primary liver cancer: an analysis of 40 cases. Shijie Xiaohua Zazhi. 2007;15:3140-3142.
25. Li B, Yu J, Wang L, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol. 2003;26 (4):e92-e99.
26. Xiao Z, Ouyang T, Yu R, Jiang X, Reng H, Wu Z. Transcatheter arterial chemoembolization combined with 3-dimensional conformal radiotherapy for patients with unresectable primary hepatic carcinoma [in Chinese]. Chin J Clinical Oncol. 2008;35(1):18-21.
27. Leng ZQ, Liang ZY, Shi S, Hu ZX. Comparison of treatment results of interventional therapy alone, radiotherapy alone, and combined interventional therapy plus radiotherapy for primary hepatic cancer [in Chinese]. Chin J Radiat Oncol. 2000;9: 99-101.
28. Zhang Z, Yang X, Wena M, Wan J. Evaluation of TACE combined with gamma-knife radiotherapy for primary hepatocellular carcinoma. J Interventional Radiology (China). 2012;7(21):596-599.
29. Zhao MH, Lang FP, Jiang QA, Ma JJ, Song YX. Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for inoperable primary liver cancer [in Chinese]. Chin J Radiat Oncol. 2006;15:39-41.
30. Peng KG, Han FS, Liu H, Song MZ. Clinical study of unresectable liver cancer treated by intraoperative hepatic arterial embolization and post-operative hyperfractionation radiotherapy [in Chinese]. Chin J Radiat Oncol. 2000;9:11-13.
31. Xue HZ, Meng GD, Wang YW, Jiang QF. Transcatheter arterial chemoembolization plus radiotherapy in the treatment of hepatocellular carcinoma [in Chinese]. Chin J Radiat Oncol. 1995;4: 84-85.
32. Lan DQ, Gong XH, Wei XL. The efficacy analysis of transcatheter hepatic arterial chemoembolization combined with radiotherapy for primary liver cancer [in Chinese]. Chin J Radiat Oncol. 2005;14:152-153.
33. Wang XH, Li JX, Gao K. Radiotherapy combined with hepatic chemoembolization in the treatment of 54 primary liver cancer. Shaxi Yixue Zazhi. 2006; 35(4):461-462.
34. Chen WJ, Yuan SF, Zhu LJ, Sun XN, Zheng W. Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma. J BUON. 2014;19(3): 692-697.
35. Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010; 78(1):180-187.
36. Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000;47(2):435-442.
37. Guo WJ, Yu EX, Liu LM, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol. 2003;9(8):1697-1701.
38. Chung YL, Jian JJ, Cheng SH, et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006;12(9):2706-2715.
39. Zeng ZC, Tang ZY, Fan J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J. 2004;10(5):307-316.
40. Liu MZ, Wang XS, Cai L, et al. External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer [in Chinese]. Ai Zheng. 2005;24(1):82-86.
41. Wang GM, Song MF, Xu H, Fei K, Shen W, Li NL. Transcatheter hepatic arterial chemoembolization plus whole-liver irradiation with the moving strip technique in the treatment of liver cancer [in Chinese]. Chin J Radiat Oncol. 1992;1:148-150.
42. Song SM, Kuang JR, Xiong K. The efficacy of transcatheter arterial chemoembolization combined with or without radiotherapy for liver cancer. Chin J Clin Oncol. 2002;29:141-142.
43. Zhang K, Yu W, Chen S, Wu J, Shao L. Effects of transcatheter hepatic arterial chemoembolization combined with radiotherapy on the survival of primary hepatic carcinoma patients with portal vein tumor thrombus. Chin J Clin Oncol. 2012;39(1):35-37.
44. Wu DH, Liu L, Chen LH. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2004;10(15):2184-2189.
45. Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(3):530-536.
46. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23(4):781-788.
47. Stillwagon GB, Order SE, Guse C, et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys. 1989;17(6):1223-1229.
48. Kuo YC, Chiu YM, Shih WP, et al. Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy. Radiat Oncol. 2011;6:76.
49. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834-846.
50. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5(1):85-91.
51. Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. J Gastroenterol Hepatol. 2001;16(8):883-889.
52. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116(5):1305-1314.
53. Lance C, McLennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(12):1697-1705.
54. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(2):224-230.
55. Seinstra BA, Defreyne L, Lambert B, et al. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials. 2012;13:144.
56. Urata K, Matsumata T, Kamakura T, Hasuo K, Sugimachi K. Lipiodolization for unresectable hepatocellular carcinoma: an analysis of 205 patients using univariate and multivariate analysis. J Surg Oncol. 1994;56(1):54-58.
57. Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol. 1993;23(2):105-109.
58. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967;67(2):337-348.
59. Price J, Chan M, Hamilton-Wood C, Chronos NA, Mok SD, Metreweli C. Sonographic diagnosis of portal vein invasion in patients with hepatocellular carcinoma: comparison with arterial portography. Clin Radiol. 1990;41(1):9-12.
60. Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol. 2002;25(2):189-193.
61. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14(10):1025-1033.
62. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397-401.
63. Kang SD, Kim JW, Jwa YJD, et al. Treatment of hepatocellular carcinoma in elderly patients. Hepatogastroenterology. 2014;61(135):2001-2008.